Dr. Yu received his Bachelor degree from Medical college of Nanchang University in 1995, then got his Master degree in Tumor Immunology Department in the Medical College in 1998 and his PhD in tumor genetics from Cancer Research Institute in Xiangya Medical School in Central South University in 2001. He had his postdoctoral training in Pharmacology Department at University of Pennsylvania from 2002 to 2006, and then worked as Research Associate (2006) and Research Assistant Professor (2009) in the Institution for Translational Medicine and Therapeutics at University of Pennsylvania. He joined the Institute of Nutritional Sciences in 2009. Currently, research efforts in Dr. Yu’s laboratory are mainly focused on: i) COX, w-3 fatty acid, PGs in cardiovascular remodeling; 2) PG and their receptors in metabolic disorders and related vascular complications; 3) Food contamination and cardiovascular toxicity. Dr. Yu has been engaged in studying cyclooxygenases (COXs) and their down-stream pathways involved in inflammatory response and cardiovascular diseases over 17 years. During the past several years, his work revealed the molecular mechanisms for COX-2 derived prostanglandin E2 (PGE2) involvement in injury-induced arterial remodeling; and found the unique role of COX-2 in blood pressure regulation and thrombogenesis; discovered COX downstream PGE2 receptor-EP3 mediates pulmonary vascular remodeling in pulmonary hypertension; uncovered the underlying mechanisms for COX-1 derived PGE2 in the pathogenesis of aspirin intolerant asthma, discovered the mechanism for regulation of vitamin D on COX-2 expression in macrophage; found COX-1 derived thromboxane A2 (TxA2) is required for B cell development; and also revealed COX-derived PGI2 in hepetocytes promotes gluconeogenesis response to fasting . These work was published in Nat Med, Sci Transl Med. J Clin Invest. J. Exp Med, Circ Res, Blood, ATVB, J Biol Chem at al.